Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932)

被引:38
作者
Peterfy, Charles G. [1 ]
Olech, Ewa [2 ]
DiCarlo, Julie C. [1 ]
Merrill, Joan T. [3 ]
Countryman, Peter J. [1 ]
Gaylis, Norman B. [4 ]
机构
[1] Spire Sci Inc, Boca Raton, FL 33487 USA
[2] Univ Nevada, Sch Med, Div Rheumatol, Las Vegas, NV 89102 USA
[3] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA
[4] Arthrit & Rheumat Dis Specialties, Aventura, FL 33180 USA
关键词
ARTICULAR-CARTILAGE; STRUCTURAL DAMAGE; MRI; KNEE; QUANTIFICATION;
D O I
10.1186/ar4202
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Magnetic resonance imaging (MRI) is increasingly being used in clinical trials of rheumatoid arthritis (RA) because of its superiority over x-ray radiography (XR) in detecting and monitoring change in bone erosion, osteitis and synovitis. However, in contrast to XR, the MRI scoring method that was used in most clinical trials did not include cartilage loss. This limitation has been an obstacle to accepting MRI as a potential alternative to XR in clinical trials. Cross-sectional studies have shown MRI to be sensitive for cartilage loss in the hands and wrist; although, longitudinal sensitivity to change has not yet been confirmed. In this study we examined the ability of MRI to monitor change in cartilage loss in patients with RA in a multi-site clinical trial setting. Methods: Thirty-one active RA patients from a clinical trial (IMPRESS) who were randomized equally into treatment with either rituximab + methotrexate or placebo + methotrexate had MRI of the dominant hand/wrist at baseline, 12 weeks and 24 weeks at 3 clinical sites in the US. Twenty-seven of these patients also had XR of both hands/wrists and both feet at baseline and 24 weeks. One radiologist scored all XR images using the van der Heijde-modified Sharp method blinded to visit order. The same radiologist scored MR images for cartilage loss using a previously validated 9-point scale, and bone erosion using the Outcome Measures in Rheumatology Clinical Trials (OMERACT) RA MRI Score (RAMRIS) blinded to visit order and XR scores. Data from the two treatment arms were pooled for this analysis. Results: Mean MRI cartilage score increased at 12 and 24 weeks, and reached statistical significance at 24 weeks. XR total Sharp score, XR erosion score and XR joint-space narrowing (JSN) score all increased at 24 weeks, but only XR total Sharp score increased significantly. Conclusions: To our knowledge, this is the first publication of a study demonstrating MRI's ability to monitor cartilage loss in a multi-site clinical trial. Combined with MRI's established performance in monitoring bone erosions in RA, these findings suggest that MRI may offer a superior alternative to XR in multi-site clinical trials of RA.
引用
收藏
页数:10
相关论文
共 25 条
[1]   Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis [J].
Cohen, Stanley B. ;
Dore, Robin K. ;
Lane, Nancy E. ;
Ory, Peter A. ;
Peterfy, Charles G. ;
Sharp, John T. ;
van der Heijde, Desiree ;
Zhou, Lifen ;
Tsuji, Wayne ;
Newmark, Richard .
ARTHRITIS AND RHEUMATISM, 2008, 58 (05) :1299-1309
[2]  
Conaghan P, 2010, ARTHRITIS RHEUM, V62, pS759
[3]   Magnetic resonance imaging (MRI) of articular cartilage in knee osteoarthritis (OA): morphological assessment [J].
Eckstein, F. ;
Cicuttini, Flavia M. ;
Raynauld, J. -P. ;
Waterton, J. C. ;
Peterfy, C. .
OSTEOARTHRITIS AND CARTILAGE, 2006, 14 :A46-A75
[4]   Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial [J].
Genant, H. K. ;
Peterfy, C. G. ;
Westhovens, R. ;
Becker, J-C ;
Aranda, R. ;
Vratsanos, G. ;
Teng, J. ;
Kremer, J. M. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (08) :1084-1089
[5]   METHODS OF ASSESSING RADIOGRAPHIC CHANGE IN RHEUMATOID-ARTHRITIS [J].
GENANT, HK .
AMERICAN JOURNAL OF MEDICINE, 1983, 75 (6A) :35-47
[6]   An Oral Syk Kinase Inhibitor in the Treatment of Rheumatoid Arthritis A Three-Month Randomized, Placebo-Controlled, Phase II Study in Patients With Active Rheumatoid Arthritis That Did Not Respond to Biologic Agents [J].
Genovese, Mark C. ;
Kavanaugh, Arthur ;
Weinblatt, Michael E. ;
Peterfy, Charles ;
DiCarlo, Julie ;
White, Michael L. ;
O'Brien, Maryann ;
Grossbard, Elliott B. ;
Magilavy, Daniel B. .
ARTHRITIS AND RHEUMATISM, 2011, 63 (02) :337-345
[7]  
Genovese MC, 2008, ARTHRITIS RHEUM, V58, pS369
[8]   Recent Advances in MRI of Articular Cartilage [J].
Gold, Garry E. ;
Chen, Christina A. ;
Koo, Seungbum ;
Hargreaves, Brian A. ;
Bangerter, Neal K. .
AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 193 (03) :628-638
[9]   Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies [J].
Keystone, E. ;
Emery, P. ;
Peterfy, C. G. ;
Tak, P. P. ;
Cohen, S. ;
Genovese, M. C. ;
Dougados, M. ;
Burmester, G. R. ;
Greenwald, M. ;
Kvien, T. K. ;
Williams, S. ;
Hagerty, D. ;
Cravets, M. W. ;
Shaw, T. .
ANNALS OF THE RHEUMATIC DISEASES, 2009, 68 (02) :216-221
[10]   Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year [J].
Kremer, Joel M. ;
Blanco, Ricardo ;
Brzosko, Marek ;
Burgos-Vargas, Ruben ;
Halland, Anne-Marie ;
Vernon, Emma ;
Ambs, Petra ;
Fleischmann, Roy .
ARTHRITIS AND RHEUMATISM, 2011, 63 (03) :609-621